Richard J. Harvey

Richard J. Harvey

Auto-generated profile, based on publicly available information

Richard J. Harvey

Dementia Research Group, National Hospital for Neurology and Neurosurgery, London, UK

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2003 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
RHR J Harvey
R J Harvey
MSM Skelton-Robinson
M Skelton-Robinson
MRM N Rossor
M N Rossor
Objectives: To determine the prevalence of dementia in people under the age of 65 in a large catchment area, and use these figures to estimate the number of younger people affected by dementia in the UK. Design: Epidemiological catchment area prevalence survey. Setting: The London boroughs of Kensington and Chelsea, Westminster, and Hillingdon with a total population of 567 500 people. Participants: All residents of the catchment area with dementia, where the illness began before the age of 65 years. Participants were notified to the study by medical and care professionals. The diagnosis and age of onset was established from all available health and social care records. In total, 227 people were identified, of whom 185 fulfilled the inclusion criteria of having a dementia which started before their 65th birthday. Main outcome measures: Diagnosis of dementia and differential diagnosis of the cause of the dementia. Results: The prevalence of dementia in those aged 30–64 was 54.0 per 100 000 (95% CI 45.1 to 64.1 per 100 000). For those aged 45–64 years, the prevalence was 98.1 per 100 000 (95% CI 81.1 to 118.0 per 100 000). From the age of 35 onwards, the prevalence of dementia approximately doubled with each 5 year increase in age. Extrapolating these figures nationally suggests that there are 18 319 (15 296–21 758) people with dementia under the age of 65 in the UK. Conclusions: The study confirms previous “guestimates” of the number of younger people affected by dementia in UK. The prevalence figures generated are robust, and are supported by other smaller and targeted prevalence surveys. The prevalence figures provided by this study will allow health planners to accurately estimate need and plan services.

18 June 2018 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
JBJacqueline Susan Birks
Jacqueline Susan Birks
RHRichard J Harvey
Richard J Harvey

1 March 2000 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
NFNick C. Fox
Nick C. Fox
SCSimon Cousens
Simon Cousens
RSRachael Scahill
Rachael Scahill
RHRichard J. Harvey
Richard J. Harvey
MRMartin N. Rossor
Martin N. Rossor
ALZHEIMER DISEASE (AD) is characterized by gradual cognitive decline and progressive cerebral atrophy. At autopsy, the histopathological disease hallmarks of amyloid plaques and neurofibrillary tangles are accompanied by widespread synaptic and neuronal loss. Atrophy is a macroscopic consequence of these cellular losses that can be visualized in life using computed tomography or magnetic resonance imaging (MRI).1

28 January 2003 in Neurology
Verified
Journal Article
Closed access
PDF file
JJJ.C. Janssen
J.C. Janssen
JBJ.A. Beck
J.A. Beck
TCT.A. Campbell
T.A. Campbell
ADA. Dickinson
A. Dickinson
NFN.C. Fox
N.C. Fox
JCJ. Collinge
J. Collinge
Background: Three causative genes have been identified for autosomal dominant AD. Objective: To determine the proportion of patients with early onset AD with a positive family history accounted for by mutations in these genes. Methods: A mutational analysis of the amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) genes was performed in 31 probands with probable or definite AD from UK families with an age at onset (AAO) <61 years. Results: The mean AAO was 46.9 years (median 45 years; range 33 to 60 years). The majority of patients (23 of 31; 74%) fulfilled recognized criteria for autosomal dominant inheritance. In 17 (55%) probands the authors identified eight novel PSEN1 sequence variants and eight recognized pathogenic mutations. In 4 (13%) probands the authors identified one novel APP sequence variant (H677R) and two recognized mutations. Thus in this series 21 of 31 (68%) probands were associated with a sequence variant in APP or PSEN1. Nine of the 11 (82%) probands with neuropathologically confirmed AD who additionally fulfilled recognized criteria for autosomal dominant inheritance were associated with a sequence variant in APP or PSEN1. The 10 patients in whom the authors were unable to identify a mutation in APP, PSEN1, or PSEN2 were older than the probands with sequence variants (55.4 vs 44.7 years: p = 0.001). Conclusions: Sequence variants in APP and PSEN1 accounted for the majority of neuropathologically confirmed autosomal dominant early onset AD; no mutations in PSEN2 were detected. There may be a further genetic factor involved in the etiology of autosomal dominant early onset AD.

25 January 2006 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
JBJacqueline Susan Birks
Jacqueline Susan Birks
RHRichard J Harvey
Richard J Harvey

22 February 2000 in Neurology
Verified
Journal Article
Closed access
PDF file
NFN.C. Fox
N.C. Fox
RJR. Jenkins
R. Jenkins
SLS.M. Leary
S.M. Leary
VSV.L. Stevenson
V.L. Stevenson
NLN.A. Losseff
N.A. Losseff
ATA.J. Thompson
A.J. Thompson
Objective: To assess the potential of registered volumetric MRI in measuring rates of atrophy in MS. Background: Pathologic and imaging studies suggest that the development of permanent neurologic impairment in MS is associated with progressive brain and spinal cord atrophy. Atrophy has been suggested as a potential marker of disease progression. Conventional atrophy measurements requiring manual outlining are time-consuming and subject to reproducibility problems. Registration of serial MRI may offer a useful alternative in that cerebral losses may be measured directly from automated subtraction of brain volumes. Methods: Twenty-six patients with MS and 26 age- and gender-matched controls had two volumetric brain MR studies 1 year apart. Baseline brain and ventricular volumes were measured using semiautomated techniques, and follow-up scans were registered to baseline. Rates of cerebral atrophy were calculated directly from the registered scans. Results: Baseline brain volumes in the MS group were smaller (mean difference 78 mL [95% CI 13 to 143; p = 0.02]) and ventricular volumes greater (mean difference 12 mL [95% CI 6 to 18; p < 0.001]) than controls. The rate of cerebral atrophy in the MS group (0.8% per year) was over twice that of controls (0.3%), and the rate of ventricular enlargement was five times greater than the controls (1.6 versus 0.3 mL/year). Conclusion: Progressive cerebral atrophy is an important feature of MS. Registration-based measurements are sensitive and reproducible, allowing progressive atrophy to be detected within 1 year and may have potential as a marker of progression in monitoring therapeutic trials.